; and (B) not later than 2 years after the date of enactment of the Securing America’s Medicine Cabinet Act of 2020 , issue final guidance with respect to the implementation of such program. (3) Report The Secretary shall make available on the internet website of the Food and Drug Administration an annual report on the progress of the program under this section. . 3. National Center of Excellence in Advanced Pharmaceutical Manufacturing Chapter X of the Federal Food, Drug, and Cosmetic Act ( 21 U.S.C. 391 et seq.) is amended by adding at the end the following: 1015. National Center of Excellence in Advanced Pharmaceutical Manufacturing (a) In general The Secretary shall designate institutions of higher education as National Centers of Excellence in Advanced Pharmaceutical Manufacturing, including continuous pharmaceutical manufacturing. (b) Eligibility To be eligible for designation under subsection (a) an entity shall— (1) be an institution of higher education; (2) demonstrate— (A) the physical and technical capacity for research and development of advanced pharmaceutical manufacturing; (B) a record of transferring scientific knowledge to the marketplace; (C) scalable manufacturing knowledge, which may be through collaborations of other institutions of higher education, biopharmaceutical manufacturers, or other entities; (D) the ability to train a future workforce for research on and implementation of advanced pharmaceutical manufacturing; and (E) the ability to support Federal agencies with technical assistance for advanced pharmaceutical technologies, with an emphasis on creating a secure national pharmaceutical stockpile and the ability to rapidly address drug shortages